Australia’s nuclear imaging agents market to hit $30m by 2036 | Healthcare Asia Magazine
, Australia
Photo from Envato

Australia’s nuclear imaging agents market to hit $30m by 2036

Its growth is driven by a rise in prostate cancer cases.

Australia’s nuclear imaging agents market is projected to reach $30m by 2036, according to a GlobalData report.

The sector’s expansion is attributed to the increasing incidence of prostate cancer and a shift towards precision diagnostics.

Australia accounted for approximately 15% of the Asia-Pacific market in 2024.

The increased uptake of agents like prostate-specific membrane antigen (PSMA) PET is also contributing to market growth.

“Historically, detecting prostate cancer has been challenging due to the limitations in conventional imaging,” said Shagufta Hasan, Medical Devices Analyst at GlobalData.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!